ReviewCNS & neurological disorders drug targets2010
Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.
Review in CNS & neurological disorders drug targets, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Growth hormone secretagogue receptor and cannabinoid receptor type 1 intersection in the mouse brain.Brain structure & function · 2024Article
- Article
- Review
- Disruption of 5-hydroxytryptamine 1A receptor and orexin receptor 1 heterodimer formation affects novel G protein-dependent signaling pathways and has antidepressant effects in vivo.Translational psychiatry · 2022Article
- Development of a New Polymeric Nanocarrier Dedicated to Controlled Clozapine Delivery at the Dopamine DPolymers · 2021Review
- Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity.International journal of molecular sciences · 2020Review
- G Protein-Coupled Receptor Heteromers as Putative Pharmacotherapeutic Targets in Autism.Frontiers in cellular neuroscience · 2020Review
- Article
- The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.Pharmacological reviews · 2019Review
- Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?Frontiers in molecular neuroscience · 2019Review
- Importance of GPCR-Mediated Microglial Activation in Alzheimer's Disease.Frontiers in cellular neuroscience · 2018Review
- Functional associations among G protein-coupled neurotransmitter receptors in the human brain.BMC neuroscience · 2014Article
- Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function.Frontiers in pharmacology · 2014Review
- Insights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes.Neural regeneration research · 2013Review
- Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon.International journal of molecular sciences · 2013Review
- B-cell lymphoma gene regulatory networks: biological consistency among inference methods.Frontiers in genetics · 2013Article
- G protein-coupled receptor heterocomplexes in neuropsychiatric disorders.Progress in molecular biology and translational science · 2013Review
- Activation of tachykinin, neurokinin 3 receptors affects chromatin structure and gene expression by means of histone acetylation.Peptides · 2012Article
- mGlu5 Receptor Functional Interactions and Addiction.Frontiers in pharmacology · 2012Article
- Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors.Neuropharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Because G protein-coupled receptors (GPCRs) are numerous, widely expressed and involved in major physiological responses, they represent a relevant therapeutic target for drug discovery, particularly regarding pharmacological treatments of neurological disorders. Among the biological phenomena regulating receptor function, GPCR heteromerization is an important emerging area of interest and investigation. There is increasing evidence showing that heteromerization contributes to the pharmacological heterogeneity of GPCRs by modulating receptor ontogeny, activation and recycling. Although in many cases the physiological relevance of receptor heteromerization has not been fully established, the unique pharmacological and functional properties of heteromers are likely to lead to new strategies in clinical medicine. This review describes the main GPCR heteromers and their implications for major neurological disorders such as Parkinson's disease, schizophrenia and addiction. A better understanding of molecular mechanisms underlying drug interactions related to the targeting of receptor heteromers could provide more specific and efficient therapeutic agents for the treatment of brain diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.